Screening for basal marker expression is necessary for decision of therapeutic strategy for triple‐negative breast cancer

Sasa, Mitsunori; Bando, Yoshimi; Takahashi, Masako; Hirose, Toshiyuki; Nagao, Taeko

doi:10.1002/jso.20906

Cited by 42 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, no statistically significant association could be seen between prognostic parameters considered here and the two subtypes in agreement with some studies (Niwińska et al, 2010;Choccalingam et al, 2012). Conversely several studies have shown that the basal type is associated with tumor size and nuclear grade (Nishimura and Arima, 2008;Sasa et al, 2008;Iwase et al, 2010). Our limited study population may be the reason behind non-association.…”

Section: Discussionsupporting

confidence: 87%

Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India

Dogra¹,

Doval²,

Sardana³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India

Dogra¹,

Doval²,

Sardana³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The use of expanded surrogate immunopanels including CK 5/6 and EGFR has been suggested recently to exclude nonbasal cases, which have better outcomes than basal cases. 32,33 The survival differed significantly between the TNBC patients who were positive for basal markers (CK5/6 1 /EGFR 1 ) and the other patients (Supp. Info.…”

Section: Discussionmentioning

confidence: 99%

Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy

Uhm

Park

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this study was to evaluate the role of platinum-containing chemotherapy for metastatic triple-negative breast cancer (TNBC) patients in terms of the response rate (RR) and progression-free survival. A second aim was to characterize the clinical behavior at the time of relapse of TNBC. We retrospectively analyzed the clinical outcomes of patients with metastatic breast cancer who received taxane-platinum chemotherapy as the first-or second-line treatment, focusing on the TN phenotype. In total, 257 patients with metastatic breast cancer received platinum-containing chemotherapy at Samsung Medical Center from 1999 to 2006. Of these patients, 106 patients with available data on estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER2) receptor status received taxane-platinum regimen as the first-or second-line treatment. The overall RR of patients with TNBC was 39%. This rate did not differ significantly from those of patients with other phenotypes. The time to death after chemotherapy (19 vs. 50 months, p 5 0.037) and overall survival (OS) (21 vs. 56 months, p 5 0.030) differed significantly between patients with TNBC and non-TNBC. TNBC showed a unique locoregional infiltration pattern at relapse, which might reflect its aggressive clinical behavior. Despite the similar response to platinum-containing chemotherapy, patients with TNBC had a shorter OS than patients with non-TNBC. The implication of TN phenotype as poor prognostic factor is uncertain, because it needs to be defined whether poor outcome is related to the rapid growing characteristics of tumor itself or the resistance to drug therapy. Further prospective studies are warranted. ' 2008 Wiley-Liss, Inc.Key words: triple-negative breast cancer; platinum chemotherapy; BRCA1 Human breast cancer is a heterogeneous group of diseases, encompassing a number of distinct biological entities that differ in their behavior, outcome and response to therapy.1,2 DNA microarray analysis has revealed 5 subtypes of breast cancer: luminal A, luminal B, basal cell-like, human epidermal growth factor receptor-2 (HER2) positive and estrogen receptor (ER) negative, and normal-like. These subtypes have different prognoses and need different systemic treatment strategies.3,4 The basal cell-like tumors typically lack or show low expression of HER2 and ER, and exhibit a high expression level of genes characteristic of basal epithelial cells.1,4-7 These tumors might share many clinical and biologic behaviors with triple-negative breast cancers (TNBCs), which lack of expression of ER, progesterone receptor (PgR) and HER2. 5,8 However, although most basal cell-like cancers do not express ER, PgR or HER2, there is incomplete overlap between basal cell-like breast cancer and TNBC. 5,[8][9][10] The TN phenotype of breast cancer is characterized by more aggressive clinical behavior and poorer prognosis compared with the other subtypes, which likely reflect this subtype's high proliferative capacity and the lack of targeted therapies such as convent...

show abstract

“…Of the 1726 tumours informative for ER, PR and HER2, 282 (16.3%) showed a triple-negative phenotype. Of these, 165 tumours expressing one or more of the basal markers (CK5/6, CK14, CK17 and/or EGFR) 3,[18][19][20] and with haematoxylin-andeosin-stained slides containing sufficient tumour for assessment were included in this study.…”

Section: Methodsmentioning

confidence: 99%

Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast

Marginean

Rakha

et al. 2010

Modern Pathology

View full text Add to dashboard Cite

Medullary carcinomas have a better prognosis than other grade 3 mammary carcinomas, but they typically show basal-like biological features, which are associated with a poor prognosis. In this study we examined the associations and prognostic relevance of medullary histological features in a series of 165 invasive carcinomas with a basal-like phenotype: triple-negative (oestrogen receptor, progesterone receptor, HER2) and expressing at least one basal marker (CK5/6, CK14, CK17 or EGFR). The following histological features were associated with each other: prominent inflammation, anastomosing sheets, absence of fibrosis, absence of infiltrative margin and absence of gland formation. Prominent inflammation and anastomosing sheets in at least 30% of the tumour were associated with a better prognosis on univariate analysis. The combination of these two features (a simplified definition of medullary-like type) was present in 17% of tumours and was an independent prognostic factor on multivariate analysis. This simplified definition had good inter-observer reproducibility (j ¼ 0.61) and is worthy of more detailed assessment in an unselected group of mammary carcinomas. A fibrotic focus was present in 36% of carcinomas. Only 3% of tumours with a fibrotic focus had features of medullary-like carcinomas. Fibrotic focus of greater than 30% of the tumour was associated with a poor prognosis. This study emphasizes the heterogeneity of morphology and behaviour of triple-negative basal-like carcinomas.

show abstract

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple‐negative breast cancer

Cited by 42 publications

References 23 publications

Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India

Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India

Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy

Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast

Contact Info

Product

Resources

About